Sionna Therapeutics, Inc. (SION) Stock Price & Analysis
Sionna Therapeutics, Inc. (SION) rose 0.54% to USD 33.69 as of June 10, 2026 at 05:57 UTC, according to Nexqual real-time market data.
SION last closed at USD 33.51; the session ranged USD 32.36–35.19 on volume of 312,864 shares. Market capitalization is $1.52B, with a 52-week range of USD 13.51–48.45 (NGM). Source: Nexqual, June 10, 2026 at 05:57 UTC.
Key Statistics (as of June 10, 2026 at 05:57 UTC)
| Price | USD 33.69 |
|---|---|
| Change | ▲ 0.54% (up) |
| Previous Close | USD 33.51 |
| Open | USD 32.58 |
| Day Range | USD 32.36 – 35.19 |
| 52-Week Range | USD 13.51 – 48.45 |
| Volume | 312,864 shares |
| Market Cap | $1.52B |
| Exchange | NGM |
Technical Analysis (SION)
Nexqual's technical model rates SION "SELL" based on 2 bullish and 5 bearish signals across 123 daily candles, as of June 10, 2026 at 05:57 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 34.23 (neutral) |
| vs SMA50 | Below (USD 40.34) |
| MACD | -1.25 (negative) |
Analyst Ratings (SION)
Wall Street analysts rate SION "Buy" based on 10 analysts, with a mean price target of USD 51.6 (range USD 23–63), per Nexqual as of June 10, 2026 at 05:57 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 10 |
| Mean Target | USD 51.6 |
| High Target | USD 63 |
| Low Target | USD 23 |
| Buy / Hold / Sell | 9 / 1 / 1 |
Earnings (SION)
| Next Earnings Date | 2026-08-10 |
|---|---|
| EPS Estimate | USD -0.64 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.6 vs est -0.5 ▼ miss |
| 2025-12-31 | USD -0.46 vs est -0.54 ▲ beat |
| 2025-09-30 | USD -0.46 vs est -0.48 ▲ beat |
| 2025-06-30 | USD -0.41 vs est -0.45 ▲ beat |
Source: Nexqual, June 10, 2026 at 05:57 UTC.
Financials & Fundamentals (SION)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -26.74% |
| Debt / Equity | 2.91 |
| Current Ratio | 22.6 |
| Total Cash | $216.15M |
| Total Debt | $8.38M |
| Free Cash Flow | $-45.70M |
Source: Nexqual, June 10, 2026 at 05:57 UTC.
Financial Health Score (SION)
Nexqual rates Sionna Therapeutics, Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 05:57 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $216M cash vs $8M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$72M |
| Efficiency | Critical — ROE -27%, ROA -18.3% |
Ownership (SION)
| Insider Ownership | +6.85% |
|---|---|
| Institutional Ownership | +100.18% |
| Shares Outstanding | 45.15M |
| Float | 16.80M |
| Short % of Float | +16.68% |
Source: Nexqual, June 10, 2026 at 05:57 UTC.
Leadership (SION)
Sionna Therapeutics, Inc. is led by Michael Cloonan (age 53), President, CEO & Director, per Nexqual as of June 10, 2026 at 05:57 UTC.
| President, CEO & Director | Michael Cloonan (age 53) |
|---|---|
| Chief Financial Officer | Elena H. Ridloff C.F.A. (age 45) |
| Vice President of Programs, Portfolio & Operations | Meghan Bagshaw |
| Vice President of Information & Technology | Andy Chu |
| Vice President of Corporate Communications | Sarah J. Spencer |
Major Backers & Investors (SION)
Notable institutional backers of Sionna Therapeutics, Inc. include RA Capital Management, L.P., TPG GP A, LLC, Orbimed Advisors LLC., according to Nexqual as of June 10, 2026 at 05:57 UTC.
Active Investors
| Investor | Stake |
|---|---|
| RA Capital Management, L.P. | 21.94% |
| TPG GP A, LLC | 14.39% |
| Orbimed Advisors LLC. | 7.82% |
| Viking Global | 7.08% |
| Atlas Venture Life Science Advisors, LLC | 6.63% |
| Enavate Sciences Gp, LLC | 5.49% |
| JPMorgan | 4.85% |
| Jennison Associates LLC | 3.21% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 4.13% |
Source: Nexqual, June 10, 2026 at 05:57 UTC.
From Sionna Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-02)
Key Strengths & Strategy (as disclosed to the SEC)
- We have developed a broad patent estate and expect to expand and protect our proprietary know-how and intellectual property.
- While we have prioritized development of a proprietary dual combination, we believe both development pathways offer attractive commercial opportunities. 10 Table of Contents Figure 1 Our Pipeline The following table summarizes our clinical stage pipeline: Figure 2 Our proprietary portfolio is anchored by our NBD1 stabilizers and our complementary modulators.
- We believe the model allows us to determine the target exposure needed to achieve a desired level of clinical activity, such as the level of improvement in a patient's forced expiratory volume in one second ("FEV 1" ), a measure of lung function, and sweat chloride level, the clinical biomarker of CFTR function.
- Our Approach and Leveraging the CFHBE Model Our programs leverage an industry standard, clinically predictive CFHBE model to measure CFTR protein function in vitro.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| MAZE | Maze Therapeutics, Inc. | USD 23.93 | ▼ 1.4% |
| BCAX | Bicara Therapeutics Inc. | USD 20.56 | ▲ 2.8% |
| UPB | Upstream Bio, Inc. | USD 6.69 | ▼ 5.11% |
| AARD | Aardvark Therapeutics, Inc. | USD 3.58 | ▼ 2.72% |
| MBX | MBX Biosciences, Inc. | USD 29.87 | ▼ 1.35% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 05:57 UTC. This page is informational and not investment advice.